HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Grass, D. S. Articles by Swanson, M. E. Search for Related Content PubMed PubMed Citation Articles by Grass, D. S. Articles by Swanson, M. E. Social Bookmarking                      What's this?

Journal of Lipid Research, Vol 36, 1082-1091, Copyright © 1995 by Lipid Research, Inc.

ARTICLES

Transgenic mice expressing both human apolipoprotein B and human CETP have a lipoprotein cholesterol distribution similar to that of normolipidemic humans

DS Grass, U Saini, RH Felkner, RE Wallace, WJ Lago, SG Young and ME Swanson
DNX Biotherapeutics, Inc., Princeton, NJ 08540, USA.

Transgenic mice expressing both human apolipoprotein (apo) B and human cholesteryl ester transfer protein (CETP) have been developed. When fed a normal mouse chow diet, the apoB/CETP double transgenic animals had threefold higher serum CETP activity than humans and had human apoB levels that were similar to those of normolipidemic humans. When compared with nontransgenic mice, the total serum cholesterol levels in the female apoB/CETP transgenic animals were increased significantly. Serum HDL cholesterol levels were decreased significantly in both male and female apoB/CETP transgenic animals. The percentages of the total cholesterol within the HDL, LDL, and VLDL fractions of the apoB/CETP animals were approximately 30%, 65%, and 5%, respectively, similar to the distribution of cholesterol in the plasma of normolipidemic humans. Thus, by expressing both human apoB and human CETP, the lipoprotein cholesterol distribution in the serum of a chow-fed mouse was transformed into one that resembles a human profile.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. Zadelaar, R. Kleemann, L. Verschuren, J. de Vries-Van der Weij, J. van der Hoorn, H. M. Princen, and T. Kooistra Mouse Models for Atherosclerosis and Pharmaceutical Modifiers Arterioscler. Thromb. Vasc. Biol., August 1, 2007; 27(8): 1706 - 1721. [Abstract] [Full Text] [PDF]

				M. Westerterp, C. C. van der Hoogt, W. de Haan, E. H. Offerman, G. M. Dallinga-Thie, J. W. Jukema, L. M. Havekes, and P. C.N. Rensen Cholesteryl Ester Transfer Protein Decreases High-Density Lipoprotein and Severely Aggravates Atherosclerosis in APOE*3-Leiden Mice Arterioscler. Thromb. Vasc. Biol., November 1, 2006; 26(11): 2552 - 2559. [Abstract] [Full Text] [PDF]

				S. U. Naik, X. Wang, J. S. Da Silva, M. Jaye, C. H. Macphee, M. P. Reilly, J. T. Billheimer, G. H. Rothblat, and D. J. Rader Pharmacological Activation of Liver X Receptors Promotes Reverse Cholesterol Transport In Vivo Circulation, January 3, 2006; 113(1): 90 - 97. [Abstract] [Full Text] [PDF]

				X.-C. Jiang, T. P. Beyer, Z. Li, J. Liu, W. Quan, R. J. Schmidt, Y. Zhang, W. R. Bensch, P. I. Eacho, and G. Cao Enlargement of High Density Lipoprotein in Mice via Liver X Receptor Activation Requires Apolipoprotein E and Is Abolished by Cholesteryl Ester Transfer Protein Expression J. Biol. Chem., December 5, 2003; 278(49): 49072 - 49078. [Abstract] [Full Text] [PDF]

				X. Wang, V. Chauhan, A. T. Nguyen, J. Schultz, J. Davignon, S. G. Young, J. Boren, T. L. Innerarity, H. Rutai, and R. W. Milne Immunochemical evidence that human apoB differs when expressed in rodent versus human cells J. Lipid Res., March 1, 2003; 44(3): 547 - 553. [Abstract] [Full Text] [PDF]

				D. C. Schwenke, L. L. Rudel, M. G. Sorci-Thomas, and M. J. Thomas {alpha}-Tocopherol protects against diet induced atherosclerosis in New Zealand white rabbits J. Lipid Res., November 1, 2002; 43(11): 1927 - 1938. [Abstract] [Full Text] [PDF]

				K. K. Berneis and R. M. Krauss Metabolic origins and clinical significance of LDL heterogeneity J. Lipid Res., September 1, 2002; 43(9): 1363 - 1379. [Abstract] [Full Text] [PDF]

				Y. Kako, M. Masse, L.-S. Huang, A. R. Tall, and I. J. Goldberg Lipoprotein lipase deficiency and CETP in streptozotocin-treated apoB-expressing mice J. Lipid Res., June 1, 2002; 43(6): 872 - 877. [Abstract] [Full Text] [PDF]

				S. H. Zuckerman, G. F. Evans, J. A. Schelm, P. I. Eacho, and G. Sandusky Estrogen-Mediated Increases in LDL Cholesterol and Foam Cell–Containing Lesions in Human ApoB100CETP Transgenic Mice Arterioscler. Thromb. Vasc. Biol., June 1, 1999; 19(6): 1476 - 1483. [Abstract] [Full Text] [PDF]

				D. A. Sanan, D. L. Newland, R. Tao, S. Marcovina, J. Wang, V. Mooser, R. E. Hammer, and H. H. Hobbs Low density lipoprotein receptor-negative mice expressing human apolipoprotein B-100 develop complex atherosclerotic lesions on a chow diet: No accentuation by apolipoprotein(a) PNAS, April 14, 1998; 95(8): 4544 - 4549. [Abstract] [Full Text] [PDF]

				E. Kim and S. G. Young Genetically modified mice for the study of apolipoprotein B J. Lipid Res., April 1, 1998; 39(4): 703 - 723. [Abstract] [Full Text] [PDF]

				J. Liu, Y. L. Zhang, M. J. Spence, R. E. Vestal, P. M. Wallace, and D. S. Grass Liver LDL Receptor mRNA Expression Is Decreased in Human ApoB/CETP Double Transgenic Mice and Is Regulated by Diet as Well as the Cytokine Oncostatin M Arterioscler. Thromb. Vasc. Biol., November 1, 1997; 17(11): 2948 - 2954. [Abstract] [Full Text]